Compare DDI & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DDI | ZVRA |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 433.6M | 472.9M |
| IPO Year | 2020 | 2015 |
| Metric | DDI | ZVRA |
|---|---|---|
| Price | $9.05 | $9.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $19.00 | ★ $21.71 |
| AVG Volume (30 Days) | 70.9K | ★ 632.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.27 |
| EPS | N/A | ★ 1.16 |
| Revenue | N/A | ★ $23,612,000.00 |
| Revenue This Year | $7.63 | $333.64 |
| Revenue Next Year | $3.68 | $44.19 |
| P/E Ratio | ★ $4.31 | $7.70 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.09 | $6.19 |
| 52 Week High | $11.25 | $13.16 |
| Indicator | DDI | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 57.18 | 57.27 |
| Support Level | $8.64 | $8.61 |
| Resistance Level | $9.32 | $9.61 |
| Average True Range (ATR) | 0.31 | 0.31 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 94.29 | 83.67 |
DoubleDown Interactive Co Ltd is a developer and publisher of digital games on mobile and web-based platforms. The company is the creator of multi-format interactive entertainment experiences for casual players. The company's operating segments include the social casino games segment and the iGaming segment. The company generates the majority of its revenue from social casino games. Geographically, the company generates the majority of its revenue from the United States.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.